Hoth Therapeutics (HOTH) Competitors $0.86 +0.01 (+1.18%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends HOTH vs. AZRX, ATHA, TPST, UBX, PIRS, SPRB, APRE, CYTH, MEIP, and LSBShould you be buying Hoth Therapeutics stock or one of its competitors? The main competitors of Hoth Therapeutics include AzurRx BioPharma (AZRX), Athira Pharma (ATHA), Tempest Therapeutics (TPST), Unity Biotechnology (UBX), Pieris Pharmaceuticals (PIRS), Spruce Biosciences (SPRB), Aprea Therapeutics (APRE), Cyclo Therapeutics (CYTH), MEI Pharma (MEIP), and Lakeshore Biopharma (LSB). These companies are all part of the "medical" sector. Hoth Therapeutics vs. AzurRx BioPharma Athira Pharma Tempest Therapeutics Unity Biotechnology Pieris Pharmaceuticals Spruce Biosciences Aprea Therapeutics Cyclo Therapeutics MEI Pharma Lakeshore Biopharma Hoth Therapeutics (NASDAQ:HOTH) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations, valuation and community ranking. Does the media refer more to HOTH or AZRX? In the previous week, Hoth Therapeutics had 3 more articles in the media than AzurRx BioPharma. MarketBeat recorded 3 mentions for Hoth Therapeutics and 0 mentions for AzurRx BioPharma. AzurRx BioPharma's average media sentiment score of 0.00 beat Hoth Therapeutics' score of -0.16 indicating that AzurRx BioPharma is being referred to more favorably in the news media. Company Overall Sentiment Hoth Therapeutics Neutral AzurRx BioPharma Neutral Do institutionals and insiders hold more shares of HOTH or AZRX? 7.1% of Hoth Therapeutics shares are held by institutional investors. Comparatively, 6.3% of AzurRx BioPharma shares are held by institutional investors. 10.6% of Hoth Therapeutics shares are held by insiders. Comparatively, 7.3% of AzurRx BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor HOTH or AZRX? AzurRx BioPharma received 155 more outperform votes than Hoth Therapeutics when rated by MarketBeat users. Likewise, 74.26% of users gave AzurRx BioPharma an outperform vote while only 64.81% of users gave Hoth Therapeutics an outperform vote. CompanyUnderperformOutperformHoth TherapeuticsOutperform Votes7064.81% Underperform Votes3835.19% AzurRx BioPharmaOutperform Votes22574.26% Underperform Votes7825.74% Which has stronger valuation and earnings, HOTH or AZRX? Hoth Therapeutics is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHoth TherapeuticsN/AN/A-$7.84M-$1.61-0.53AzurRx BioPharmaN/AN/A-$32.67M-$11.50-0.06 Do analysts recommend HOTH or AZRX? Hoth Therapeutics presently has a consensus target price of $3.50, suggesting a potential upside of 306.98%. Given Hoth Therapeutics' higher probable upside, analysts clearly believe Hoth Therapeutics is more favorable than AzurRx BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33AzurRx BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has more risk & volatility, HOTH or AZRX? Hoth Therapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Is HOTH or AZRX more profitable? Hoth Therapeutics' return on equity of -81.78% beat AzurRx BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Hoth TherapeuticsN/A -81.78% -74.38% AzurRx BioPharma N/A -482.96%-258.47% SummaryHoth Therapeutics beats AzurRx BioPharma on 10 of the 15 factors compared between the two stocks. Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get Hoth Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOTH vs. The Competition Export to ExcelMetricHoth TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.87M$7.42B$5.50B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.5310.05116.1015.23Price / SalesN/A400.761,496.2597.74Price / CashN/A47.3939.7434.10Price / Book0.425.594.775.07Net Income-$7.84M$153.56M$119.06M$225.46M7 Day Performance2.38%0.13%0.80%0.37%1 Month Performance3.86%15.23%5.65%3.57%1 Year Performance-28.93%41.14%36.75%29.43% Hoth Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOTHHoth Therapeutics3.3034 of 5 stars$0.86+1.2%$3.50+307.0%-27.1%$5.94MN/A-0.534Gap UpAZRXAzurRx BioPharmaN/A$0.69+7.8%N/A+123.9%$6.42MN/A-0.0612ATHAAthira Pharma2.5581 of 5 stars$0.61+42.3%$13.83+2,183.1%-65.4%$23.29MN/A-0.2040Gap UpHigh Trading VolumeTPSTTempest Therapeutics2.245 of 5 stars$0.91-1.1%$20.75+2,181.7%-75.4%$22.92MN/A-0.5720UBXUnity Biotechnology3.9281 of 5 stars$1.31-3.7%$6.67+408.9%-29.2%$22.91M$240,000.00-0.6660Positive NewsPIRSPieris Pharmaceuticals2.3762 of 5 stars$17.30+0.3%N/A-14.4%$22.84M$20.87M-0.92140Gap DownSPRBSpruce Biosciences3.0101 of 5 stars$0.55+3.8%$5.00+812.1%-51.1%$21.94M$10.09M-0.5320Gap DownAPREAprea Therapeutics3.5958 of 5 stars$3.92+0.3%$15.50+295.4%+13.3%$21.29M$580,000.00-1.297Short Interest ↑CYTHCyclo Therapeutics2.7002 of 5 stars$0.72-4.0%$0.95+31.7%-25.2%$20.71M$1.08M-0.829Positive NewsGap UpMEIPMEI Pharma4.567 of 5 stars$3.07-1.0%$7.00+128.0%-56.3%$20.45M$65.30M1.15100Analyst ForecastNews CoverageGap DownLSBLakeshore Biopharma0.3962 of 5 stars$2.16-7.3%N/AN/A$20.11M$80.82M0.00773News CoverageGap Up Related Companies and Tools Related Companies AzurRx BioPharma Alternatives Athira Pharma Alternatives Tempest Therapeutics Alternatives Unity Biotechnology Alternatives Pieris Pharmaceuticals Alternatives Spruce Biosciences Alternatives Aprea Therapeutics Alternatives Cyclo Therapeutics Alternatives MEI Pharma Alternatives Lakeshore Biopharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HOTH) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
